Neutralizing type‐I interferon autoantibodies are associated with delayed viral clearance and intensive care unit admission in patients with COVID‐19

  • Michael S Abers
    Laboratory of Clinical Immunology & Microbiology National Institute of Allergy & Infectious Diseases National Institutes of Health Bethesda MD USA
  • Lindsey B Rosen
    Laboratory of Clinical Immunology & Microbiology National Institute of Allergy & Infectious Diseases National Institutes of Health Bethesda MD USA
  • Ottavia M Delmonte
    Laboratory of Clinical Immunology & Microbiology National Institute of Allergy & Infectious Diseases National Institutes of Health Bethesda MD USA
  • Elana Shaw
    Laboratory of Clinical Immunology & Microbiology National Institute of Allergy & Infectious Diseases National Institutes of Health Bethesda MD USA
  • Paul Bastard
    Laboratory of Human Genetics of Infectious Diseases Necker Branch INSERM U1163 Necker Hospital for Sick Children Paris France
  • Luisa Imberti
    CREA Laboratory Diagnostic Department ASST Spedali Civili di Brescia Brescia Italy
  • Virginia Quaresima
    CREA Laboratory Diagnostic Department ASST Spedali Civili di Brescia Brescia Italy
  • Andrea Biondi
    Pediatric Department and Centro Ricerca M. Tettamanti Fondazione MBBM‐Ospedale San Gerardo University of Milano‐Bicocca Monza Italy
  • Paolo Bonfanti
    Department of Infectious Diseases San Gerardo Hospital University of Milano‐Bicocca Monza Italy
  • Riccardo Castagnoli
    Laboratory of Clinical Immunology & Microbiology National Institute of Allergy & Infectious Diseases National Institutes of Health Bethesda MD USA
  • Jean‐Laurent Casanova
    Laboratory of Human Genetics of Infectious Diseases Necker Branch INSERM U1163 Necker Hospital for Sick Children Paris France
  • Helen C Su
    Laboratory of Clinical Immunology & Microbiology National Institute of Allergy & Infectious Diseases National Institutes of Health Bethesda MD USA
  • Luigi D Notarangelo
    Laboratory of Clinical Immunology & Microbiology National Institute of Allergy & Infectious Diseases National Institutes of Health Bethesda MD USA
  • Steven M Holland
    Laboratory of Clinical Immunology & Microbiology National Institute of Allergy & Infectious Diseases National Institutes of Health Bethesda MD USA
  • Michail S Lionakis
    Laboratory of Clinical Immunology & Microbiology National Institute of Allergy & Infectious Diseases National Institutes of Health Bethesda MD USA

説明

<jats:title>Abstract</jats:title><jats:p>Type‐I interferons (IFNs) mediate antiviral activity and have emerged as important immune mediators during coronavirus disease 19 (COVID‐19). Several lines of evidence suggest that impaired type‐I IFN signaling may predispose to severe COVID‐19. However, the pathophysiologic mechanisms that contribute to illness severity remain unclear. In this study, our goal was to gain insight into how type‐I IFNs influence outcomes in patients with COVID‐19. To achieve this goal, we compared clinical outcomes between 26 patients with neutralizing type‐I IFN autoantibodies (AAbs) and 192 patients without AAbs who were hospitalized for COVID‐19 at three Italian hospitals. The presence of circulating AAbs to type‐I IFNs was associated with an increased risk of admission to the intensive care unit and a delayed time to viral clearance. However, survival was not adversely affected by the presence of type‐I IFN AAbs. Our findings provide further support for the role of type‐I IFN AAbs in impairing host antiviral defense and promoting the development of critical COVID‐19 pneumonia in severe acute respiratory syndrome coronavirus 2‐infected individuals.</jats:p>

収録刊行物

被引用文献 (2)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ